Eli Lilly reported significantly stronger-than-expected Q3 2026 revenue and adjusted EPS, driven by robust sales of its metabolic drugs Mounjaro and Zepbound. The company subsequently raised its full-year revenue and EPS guidance, indicating continued strong performance and positive market sentiment.
Eli Lilly announced exceptional third-quarter 2026 financial results, significantly exceeding analyst expectations for both revenue and adjusted earnings per share. This outperformance was primarily attributed to the booming sales of its metabolic drugs, Mounjaro and Zepbound, which saw substantial year-over-year growth. The company's decision to raise its full-year guidance for both revenue and EPS signals strong confidence in its future performance and the continued demand for its key products. This is a major positive catalyst for LLY stock in the short term, as it validates the company's growth strategy and market position. For traders, the key opportunity lies in the sustained momentum of LLY, while competitors in the metabolic drug space like Novo Nordisk (NVO) might face increased pressure or be seen as lagging in growth.